Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.
1999 ◽
Vol 35
◽
pp. S315
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 1012-1012
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. TPS102-TPS102
◽
Keyword(s):
2004 ◽
Vol 2
(3)
◽
pp. 125-126
◽
Keyword(s):
2013 ◽
Keyword(s):